Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease : A prospective 9-year study
Stomrud, Erik LU
; Minthon, Lennart
LU
; Zetterberg, Henrik
LU
; Blennow, Kaj
LU
and Hansson, Oskar
LU
(2015)
In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
1(4).
p.11-403
- Abstract
INTRODUCTION: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.
METHODS: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.
RESULTS: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low... (More)
INTRODUCTION: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.
METHODS: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.
RESULTS: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low levels already at baseline.
DISCUSSION: CSF Aβ42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.
(Less)
- author
- Stomrud, Erik
LU
; Minthon, Lennart
LU
; Zetterberg, Henrik
LU
; Blennow, Kaj
LU
and Hansson, Oskar
LU
- organization
- publishing date
- 2015-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
- volume
- 1
- issue
- 4
- pages
- 11 - 403
- publisher
- Elsevier
- external identifiers
-
- scopus:84946087516
- pmid:27239521
- ISSN
- 2352-8729
- DOI
- 10.1016/j.dadm.2015.09.002
- language
- English
- LU publication?
- yes
- id
- 913ec2b1-35c6-484f-81e8-ef5900bcd55c
- date added to LUP
- 2019-05-31 13:12:31
- date last changed
- 2024-04-02 06:19:33
@article{913ec2b1-35c6-484f-81e8-ef5900bcd55c,
abstract = {{<p>INTRODUCTION: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.</p><p>METHODS: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.</p><p>RESULTS: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low levels already at baseline.</p><p>DISCUSSION: CSF Aβ42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.</p>}},
author = {{Stomrud, Erik and Minthon, Lennart and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar}},
issn = {{2352-8729}},
language = {{eng}},
number = {{4}},
pages = {{11--403}},
publisher = {{Elsevier}},
series = {{Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring}},
title = {{Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease : A prospective 9-year study}},
url = {{http://dx.doi.org/10.1016/j.dadm.2015.09.002}},
doi = {{10.1016/j.dadm.2015.09.002}},
volume = {{1}},
year = {{2015}},
}